1229895

Eli Lilly & Company — FEI 1819470

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
January 15, 2025
Fiscal Year
2025
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Indianapolis, IN (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)